re : Japanese Pharma -
Opinion sought on Kaken Pharmaceuticals
Hi to all fellow biotech & pharma investors on this thread. I'm posting here because I think my question is on-topic. Any opinions welcome..
Having researched Japan equities I recently stumbled over a midsized Japanese Pharma company that appears undervalued to me.. Kaken Pharmaceuticals .. www.kaken.co.jp
Kaken Pharmaceutical - 4521.J - 740 Yen
Y-70.3bn sales, PSR 1, P/B 2, PE 35 R&D 8%/sales
nice pipeline .. 17 compounds .. 5 approved, 5 NDA, 5 Phase 2, 2 Stage 1, 2 Preclinical, 4 Drug discovery collaborations .. noteworthy their licensing of a top SCIOS product in the past for Japan (& Asia ?). They are often in-licensing deals with Japanese biotech firms, points to an expert & vastly deployed sales-force
Other interesting Japanes firms that came to my attention:
Tanabe Seiyaku - 4508.J - 1150 Yen
Y-194bn sales, PSR 1.76, P/B 1.76, PE 17
Pipeline: 18 compounds ... 7 NDA, 3 Phase 2, 7x Trials, 1x launch
Dainippon Pharma - 4506.J - 1350 Yen
Y-159bn sales, PSR 1.44, P/B 2.10, PE 23,
Pipeline: 17 compounds ... 1 launch, 5 NDA, 1 P3, 6 P2, 4 P1
Sankyo - 4501.J - 2000 Yen
Y-545bn sales, PSR 1.68 PE 25 P/B 1.40 R&D 14%/Rev.
Pipeline: 26 compounds .. 5 filed, 2 P3, 6 P2, 10 P1, 5 PreCl
rgrds
CROSSY |
